Alternative names
MDE
Current Scheduling Status
Year(s) and type of review / ECDD meetings
Drug Class
Recommendation (from TRS)
Substance identification
(-+)-N-Ethyltenamfetamine (MDE) (CAS: 14089-52-2), chemically N-ethyl-alpha-methyl-3,4-(methylenedioxy)phenethylamine, is also known as N-ethyl MDA, 3,4-methylenedioxy-N-ethylamphetamine, N-ethyl-3,4-methylene-dioxyamphetamine, Eve, MDEA, JN-ethyl-3,4-methylenedioxyphenylisopropylamine, 1-(3,4-methylenedioxyphenyl)-2-ethylaminopropane and 3,4-methylenedioxyethamphetamine. There is one chiral carbon atom so that two stereoisomers and one racemate are possible.
Similarity to known substances and effects on the CNS
(+)-N-Ethyltenamfetamine has psychomotor stimulating properties in rodents and is neurotoxic through its damaging effects on serotonergic systems in the brain. In discrimination studies in rats, (+)-N-ethyltenamfetamine generalizes to MDMA but not to d-amfetamine or DOM. Psychotomimetic effects have been observed in humans. Thus, (+)-N-ethyltenamfetamine has a pharmacological profile similar to that of MDMA.
Dependence potential
In a baboon self-administration study, (+)-N-ethyltenamfetamine was found to have reinforcing properties. No studies are available on the dependence potential in human subjects.
Actual abuse and or/evidence of likelihood of abuse
There is evidence of abuse from the Drug Abuse Warning Network (DAWN) in the USA, and two deaths have been reported in which (+)-N-ethyltenamfetamine was detected in body fluids, together with other drugs. The substance has been identified in drug seizures in Canada, the Federal Republic of Germany, and the USA. Clandestine production has been demonstrated. There is some evidence that (+)-N-ethyltenamfetamine may pose a significant risk to public health owing to its neurotoxicity.
Therapeutic usefulness
There is no known therapeutic use for (+)-N-ethylienamfetamine.
Recommendation
On the basis of the available data concerning its pharmacological profile, dependence potential and actual abuse, the Committee rated the likelihood of abuse of (+)-Nethyltenamfetamine as moderate. The public health and social problems associated with the substance are extremely serious and it has no known therapeutic use. In the light of this assessment, the Committee recommended that (+)-N-ethyltenamfetamine be controlled under Schedule I of the Convention on Psychotropic Substances, 1971.
(-+)-N-Ethyltenamfetamine (MDE) (CAS: 14089-52-2), chemically N-ethyl-alpha-methyl-3,4-(methylenedioxy)phenethylamine, is also known as N-ethyl MDA, 3,4-methylenedioxy-N-ethylamphetamine, N-ethyl-3,4-methylene-dioxyamphetamine, Eve, MDEA, JN-ethyl-3,4-methylenedioxyphenylisopropylamine, 1-(3,4-methylenedioxyphenyl)-2-ethylaminopropane and 3,4-methylenedioxyethamphetamine. There is one chiral carbon atom so that two stereoisomers and one racemate are possible.
Similarity to known substances and effects on the CNS
(+)-N-Ethyltenamfetamine has psychomotor stimulating properties in rodents and is neurotoxic through its damaging effects on serotonergic systems in the brain. In discrimination studies in rats, (+)-N-ethyltenamfetamine generalizes to MDMA but not to d-amfetamine or DOM. Psychotomimetic effects have been observed in humans. Thus, (+)-N-ethyltenamfetamine has a pharmacological profile similar to that of MDMA.
Dependence potential
In a baboon self-administration study, (+)-N-ethyltenamfetamine was found to have reinforcing properties. No studies are available on the dependence potential in human subjects.
Actual abuse and or/evidence of likelihood of abuse
There is evidence of abuse from the Drug Abuse Warning Network (DAWN) in the USA, and two deaths have been reported in which (+)-N-ethyltenamfetamine was detected in body fluids, together with other drugs. The substance has been identified in drug seizures in Canada, the Federal Republic of Germany, and the USA. Clandestine production has been demonstrated. There is some evidence that (+)-N-ethyltenamfetamine may pose a significant risk to public health owing to its neurotoxicity.
Therapeutic usefulness
There is no known therapeutic use for (+)-N-ethylienamfetamine.
Recommendation
On the basis of the available data concerning its pharmacological profile, dependence potential and actual abuse, the Committee rated the likelihood of abuse of (+)-Nethyltenamfetamine as moderate. The public health and social problems associated with the substance are extremely serious and it has no known therapeutic use. In the light of this assessment, the Committee recommended that (+)-N-ethyltenamfetamine be controlled under Schedule I of the Convention on Psychotropic Substances, 1971.
ECDD Recommendation
Inclusion in Schedule I of the 1971 Convention on Psychotropic Substances
Link to full TRS
who_trs_787.pdf1.19 MB